Study Finds Urolithin A from Pomegranates May Enhance Heart Function in HFpEF
Heart failure is a significant global health issue, affecting an estimated 64 million people worldwide. Among these cases, approximately 50% are classified as heart failure with preserved ejection fraction (HFpEF), a condition characterized by the heart muscle's stiffness, which impairs its ability to relax and refill with blood. This can lead to symptoms such as fluid retention, fatigue, and shortness of breath. Current treatment options for HFpEF include medications and lifestyle changes, but they often do not address the underlying stiffness of the heart muscle directly.
A new study published in the journal Science Advances has uncovered promising findings regarding urolithin A, a natural compound produced in the gut microbiome when consuming foods rich in ellagitannins, such as pomegranates, berries, and walnuts. Researchers utilized both animal models and engineered human heart tissue to explore the effects of urolithin A on heart function in HFpEF. Joseph Burgoyne, PhD, a senior author of the study from King’s College London, emphasized the need for new therapies that directly target the mechanisms underlying HFpEF.
The study revealed that treatment with urolithin A led to an impressive 80% improvement in heart function in animal models compared to untreated controls. In engineered human heart tissue, urolithin A significantly enhanced tissue relaxation, indicating its potential as a therapeutic agent. Burgoyne noted that the compound targets a protein called PKG1alpha, which plays a crucial role in heart muscle relaxation.
Kevin Shah, MD, a cardiologist not involved in the study, expressed enthusiasm for the findings, highlighting the need for clinical studies to translate these results into patient care. He pointed out that HFpEF accounts for a substantial portion of heart failure cases, and while treatment options are improving, there is still a need for refined approaches based on individual patient subtypes.
Burgoyne cautioned that while the study's results are promising, there is currently insufficient evidence to recommend dietary changes, such as increasing pomegranate consumption, as a treatment for heart failure. However, he acknowledged that enhancing urolithin A production through dietary means could be beneficial in the future.
Registered dietitian Monique Richard, who also commented on the study, emphasized the connection between gut health, diet, and cardiovascular function. She noted that urolithin A is not merely a nutrient but a metabolite that arises from the interaction of certain foods with the gut microbiome. Richard suggested that the focus should be on consuming a diverse range of plant foods that promote the production of urolithin A rather than viewing it as a standalone treatment.
In conclusion, while the study presents encouraging evidence for the potential of urolithin A in improving heart function in HFpEF, further research is necessary to determine its applicability in clinical settings. The findings highlight the intricate relationship between diet, gut health, and heart function, suggesting that a holistic approach to nutrition may be key in managing heart health effectively.




